Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Nov 13;24(1):796.
doi: 10.1186/s12888-024-06146-8.

Shen-based Qigong Exercise improves cognitive impairment in stable schizophrenia patients in rehabilitation wards: a randomized controlled study

Hui Shen #  1 , Anbei Lian #  2 , Yiwen Wu  3 , Jinjing Zhou  3 , Yan Liu  3 , Liping Zhu  3 , Yi Zhang  3 , Zhenghui Yi  3 , Xiaodan Liu  4 , Qing Fan  5   6   7
Affiliations
Randomized Controlled Trial

Shen-based Qigong Exercise improves cognitive impairment in stable schizophrenia patients in rehabilitation wards: a randomized controlled study

Hui Shen et al. BMC Psychiatry. .

Abstract

Background: Cognitive impairment is common in chronic schizophrenia patients. The purpose of this study was to explore the efficacy of Shen-based Qigong Exercise (SBQE) in improving the cognitive impairment of stable schizophrenia patients in rehabilitation wards.

Methods: SBQE is derived from the theory of "body-spirit syncretism (xin shen he yi)" in traditional Chinese medicine (TCM) and is extracted from the four traditional Qigong techniques. In this 12-week, randomized, single-blind, controlled study, a total of 40 schizophrenia patients were randomly assigned to either the SBQE group or the control group. The scores for the Scale for the Assessment of Negative Symptoms (SANS) and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) were recorded at baseline and week 12, respectively.

Results: At week 12, the mean RBANS total score was 84.5 points in the SBQE group and 72.8 points in the control group. The estimated mean difference was - 11.60 points (2-sided 95% CI, -22.41 to -0.79; P = 0.04). This difference was statistically significant (time-by-group interaction effect estimates, F(1,38) = 5.07; P = 0.03).

Conclusions: Our preliminary findings indicated that SBQE led to an improvement in cognitive impairment in stable schizophrenia patients in rehabilitation wards. Further research with robust design and larger sample sizes is necessary to validate the effects of SBQE on cognitive function and psychiatric symptoms in schizophrenia, thus providing more substantial evidence for the clinical application of SBQE.

Trial registration: ClinicalTrials.gov Identifier: NCT05310955 on 22/02/2022; http://www.chictr.org.cn/ Identifier: ChiCTR2200057373 on 10/03/2022.

Keywords: Cognitive impairment; Qigong; Schizophrenia.

PubMed Disclaimer

Conflict of interest statement

Declarations Ethics approval and consent to participate The study was approved by the Shanghai Mental Health Center’s Internal Review Board (IRB). The participants signed the informed consent form after being provided with a thorough explanation of the procedures, the study’s purpose, and assurances of confidentiality. This study was conducted in accordance with the Declaration of Helsinki and relevant guidelines and regulations. Consent for publication Not applicable. Competing interests The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
SBQE for treating schizophrenia patients
Fig. 2
Fig. 2
Study flowchart
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Owen MJ, Sawa A, Mortensen PB, Schizophrenia. Lancet. 2016;388(10039):86–97. 10.1016/s0140-6736(15)01121-6. - PMC - PubMed
    1. Jauhar S, Johnstone M, McKenna PJ, Schizophrenia. Lancet. 2022;399(10323):473–86. 10.1016/s0140-6736(21)01730-x. - PubMed
    1. Charlson FJ, Ferrari AJ, Santomauro DF, Diminic S, Stockings E, Scott JG, McGrath JJ, Whiteford HA. Global Epidemiology and burden of Schizophrenia: findings from the global burden of Disease Study 2016. Schizophr Bull. 2018;44(6):1195–203. 10.1093/schbul/sby058. - PMC - PubMed
    1. Millan MJ, Fone K, Steckler T, Horan WP. Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment. Eur Neuropsychopharmacol. 2014;24(5):645–92. 10.1016/j.euroneuro.2014.03.008. - PubMed
    1. Kahn RS, Keefe RS. Schizophrenia is a cognitive illness: time for a change in focus. JAMA Psychiatry. 2013;70(10):1107–12. 10.1001/jamapsychiatry.2013.155. - PubMed

Publication types

Associated data